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Abstract
Background: Overdiagnosis of bronchopulmonary carcinoid tumors together with overtreatment can cause serious
postoperative consequences for the patient. We report of a patient with a typical bronchopulmonary carcinoid
tumor, which was initially misdiagnosed and treated as an adenocarcinoma of the lung. GnrH receptors and the
associated Raf-1/MEK/ERK-1/2-pathway are potential targets for analogs in cancer treatment. We suspected a
correlation between the lack of tumor growth, application of leuprolide and the Raf-1/MEK/ERK-1/2-pathway.
Therefore, we examined GnrH receptor status in the examined specimen.
Case presentation: In 2010 a 77 year-old male patient was shown to have a tumor mass of about 1.7 cm
diameter in the inferior lobe of the left lung. Since 2005, this tumor had hitherto been known and showed no
progression in size. The patient suffered from prostate cancer 4 years ago and was treated with TUR-P, radiation
therapy and the application of leuprolide. We conducted an explorative thoracotomy with atypical segment
resection. The first histological diagnosis was a metastasis of prostate cancer with lymphangiosis carcinomatosa.
After several immunohistochemical stainings, the diagnosis was changed to adenocarcinoma of the lung. We
conducted a re-thoracotomy with lobectomy and systematic lymphadenectomy 12 days later. The tumor stage
was pT1 N0 MX G2 L1 V0 R0. Further immunohistochemical studies were performed. We received the results 15
days after the last operation. The diagnosis was ultimately changed to typical carcinoid tumor without any signs of
lymphatic vessel invasion. The patient recovered well from surgery, but still suffers from dyspnea and lack of
physical performance. Lung function testing revealed no evidence of impairment.
Conclusion: The use of several immunohistochemical markers, careful evaluation of hematoxylin-eosin sections
and the Ki-67 labelling index are important tools in discriminating between carcinoids and other
bronchopulmonary carcinomas. Although we could not detect GnrH-receptors in the examined specimen, there
may be individual differences in expression. GnrH receptor profiles in typical and atypical carcinoids should be
scrutinized. This could lead to new therapeutical options, since the GnrH receptor has already been described on
atypical carcinoids. Clinically tested drugs such as leuprolide could come to use.
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Laennec was the first one to report on an intrabronchial
tumor mass, published posthumously in 1881. This was
the first description of a bronchial carcinoid tumor [1].
The first detailed description of a so-called bronchial
adenoma, which was probably a carcinoid tumor too,
was adduced by Mueller in 1882 [2]. The term “Karzi-
noid” was introduced by the German pathologist Obern-
dorfer in 1907 for tumors of the ileum, although
Lubarsch had described a similar case of two patients
with ileal carcinoid tumors in 1888 [3,4]. Carcinoids
represent approximately 2% of all lung tumors. 25-30%
of all neuroendocrine tumors appear in the bronchopul-
monary system. The age-adjusted incidence rates of
bronchopulmonary carcinoids and neuroendocrine
tumors in general have increased over the last 30 years
for all genders and races. This increase may be due to
improvements in histopathological diagnosis and classifi-
cation and to the more frequent use of endoscopic pro-
cedures [5-7]. The average age of diagnosis is at 60
years. Modlin et al. and others described a female pre-
dominance [8,9], whereas Quaedvlieg et al. described a
female predominance only for patients under the age of
50 years, suggesting hormonal influence [10]. Typical
carcinoids are the most common lung tumors in chil-
dren. Misdiagnosis of typical carcinoid tumors of the
lung as SCLC has been reported previously [11,12]. We
report of a patient with a typical bronchopulmonary car-
cinoid tumor, which was initially misdiagnosed as an
adenocarcinoma of the lung and also treated as such.
This led to serious postoperative consequences for the
patient. The tumor described in our case report showed
almost no progression in 5 years. GnrH receptors and
the associated Raf-1/MEK/ERK-1/2-pathway are poten-
tial targets for analogs in cancer treatment. We sus-
pected a correlation between the lack of tumor growth,
application of leuprolide and the Raf-1/MEK/ERK-1/2-
pathway. Therefore, we examined GnrH receptor status
in the examined specimen.
Case report
In March 2010 a 77 year-old male patient was shown to
have a tumor mass of about 1.7 cm diameter in the
inferior lobe of the left lung (see Figure 1). Since 2005,
this asymptomatic tumor mass had hitherto been known
with a diameter of approximately 1.7 cm. It showed
almost no increase in size and could therefore be classi-
fied as “stable disease”.T h ep a t i e n ts u f f e r e df r o mp r o s -
tate cancer 4 years ago and was treated with TUR-P,
radiation therapy and the application of leuprolide.
Other pre-existing conditions were arterial hypertension
and chronic obstructive lung disease. The physical
examination was without pathological findings. A preo-
perative PET/CT scan was not performed due to the
fact that neither a positive nor a negative PET/CT scan
result rules out a surgical intervention. Therefore, we
conducted a left anterolateral thoracotomy with atypical
segment resection for curative tumor treatment. The
pathological examination of the resected tissue revealed
a malignant tumor with a diameter of 1.5 cm. As a first
Figure 1 Transversal CT scans of the thorax from the years 2005 (left) and 2010 (right), showing a solid tumor mass in the left inferior lobe of
the lung with almost no progress in size. The tumor had a diameter of approximately 1.7 cm in both 2005 and 2010.
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with lymphangiosis carcinomatosa was assumed. Further
immunohistochemical stud i e sf o rP S A ,C K 7 ,C K 2 0a n d
TTF1 were performed. Stainings for PSA and CK20
were both negative, stainings for TTF1 showed a strong
nuclear and for CK7 a strong cytoplasmatic reaction
(see Figure 2). Therefore, the initial diagnosis of a
metastasis of prostate cancer was changed to adenocar-
cinoma of the lung. Relying on this new diagnosis, we
conducted a re-thoracotomy with lobectomy and sys-
tematic lymphadenectomy as an adequate treatment 12
days after the above-mentioned operation. The resection
m a r g i n sw e r ef r e eo ft u m o rc e l l s .T ot h i sp o i n t ,t h e
tumor stage was pT1 N0 MX G2 L1 V0. Further immu-
nohistochemical studies were performed. These revealed
cytoplasmatic expression of chromogranin A and synap-
tophysin, plasma membrane associated expression of
CD56 and a Ki-67 labelling index of approximately 5%
(see Figure 2). After re-evaluation of all results and par-
ticularly with regard to the little progress in tumor size,
the diagnosis was ultimately changed to typical broncho-
pulmonary carcinoid tumor. A re-examination of the
sample showed no invasion of tumor cells in lymphatic
vessels. The patient recovered well from surgery and
received postoperative rehabilitation therapy. In addition
lung function testing revealed no evidence of impair-
ment. Follow-up care is carried out by our department
of oncology. The typical carcinoid tumor described in
our case report showed almost no progression in 5
y e a r s .W es u s p e c t e dac o r r e lation between the lack of
tumor growth, application of leuprolide and the Raf-1/
MEK/ERK-1/2-pathway. Therefore, we examined GnrH
receptor status in the examined specimen. An expres-
sion of GnrH receptor could not be detected.
Discussion
It is generally assumed that carcinoids arise from Kul-
chitsky cells disseminated in the bronchopulmonary
mucosa [13]. Typical carcinoids (TCs) are usually well-
differentiated tumors of histologically ordered structure,
A B C
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G
Figure 2 A) HE-staining. B-G) Immunohistochemical stainings. B) Cytoplasmatic expression of CK7. C) Nuclear expression of TTF1. D)
Cytoplasmatic expression of chromogranin A. E) Cytoplasmatic expression of synaptophysin. F) Plasma membrane associated expression of CD56.
G) Ki-67 labelling index of approximately 5%.
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10 high power fields and without necrosis. A minority
of carcinoids show an atypical appearance with 2-10
mitoses per 10 high power fields, necrosis and they tend
to be more aggressive than typical carcinoids. They also
show a higher probability to metastasize, to recur and
have a worse outcome and prognosis. These are referred
to as atypical carcinoids (ACs) [14-16]. The division of
neuroendocrine tumors into different subgroups is
nowadays based on the WHO classification of 2004 [16].
Other systems like the embryogenetic classification pro-
posed by Wiliams and Sandler in 1963, which differen-
tiated between carcinoids of the foregut (lung, stomach,
duodenum, pancreas, upper jejunum), midgut (lower
jejunum, ileum, appendix, caecum) and hindgut (colon,
rectum), were too inaccurate and therefore could not
prevail [17]. 75-90% of all bronchopulmonary carcinoids
are localized central, 10-25% peripheral [18,19]. 70-90%
are identified as typical and 10-30% as atypical carci-
noids [8,20]. TCs are primarily found central and show
nodal involvement in 3-20%, whereas ACs are mostly
localized in the periphery of the tracheobronchial tree
and show nodal involvement in 48-75% [8,21]. ACs are
more often associated with smoking than TCs (62-80%).
In this regard, a correlation between typical carcinoid
histology and smoking is not very likely [6,8,22,23]. The
combination of tumor size and mean nuclear area can
be used to predict the presence or absence of regional
lymph node metastases in 80% and 94% of all cases,
respectively [24]. At the time of diagnosis, ACs usually
present at a more advanced stage than typical ones.
Therefore, an accurate histological diagnosis is essential
for further treatment [25]. Mineo et al. published in
2005 that ACs have a higher probability for developing
micrometastases, thus explaining the more aggressive
clinical behavior. Nodal micrometastases do not corre-
late with tumor size and stage, implying that even small
tumors located in the periphery of the tracheobronchial
tree may metastasize. Immunohistochemical detection of
micrometastases by using chromoganin A and cytokera-
tin as markers can help to identify patients with a high
risk of recurrence, allowing a more accurate staging
[26]. Atypical and typical carcinoid tumors are charac-
terized by a frequent deletion of 11 q material including
t h eM E N 1g e n el o c u s .L o s s e so f1 0qa n d1 3q
sequences are more often associated with atypical than
with typical carcinoids, making further cytogenetic dif-
ferentiation possible and probably explaining the more
aggressive behavior of ACs [27].
TTF1 is a transcription factor with a molecular weight
of 38 kDa, which plays an important role in lung mor-
phogenesis and the expression of surfactant factor. It is
considered as a dependable marker in distinguishing
between primary and metastatic lung adenocarcinomas
and can also be helpful in discerning pulmonary neu-
roendocrine tumors from gastrointestinal ones. The
diagnostic value seems to depend on the used antibody
clone [28-30]. According to the literature, the expression
rate in adenocarcinomas of the lung varies between 73-
92% [31-34]. The described expression rate of TTF1 in
bronchopulmonary carcinoids also shows a high varia-
bility. Rugge et al. and Sturm et al. were not able to
detect TTF1-expression in either TCs or ACs. Further-
more, Sturm et al. showed a positive TTF1-expression
in 85.5% and 49% of all studied SCLCs and LCNECs,
respectively. According to the authors, this could imply
that carcinoids derive from different stem cells than
SCLCs and non-SCLCs including LCNECs [35,36]. In
this context it is worth mentioning a study published by
Sampietro et al., which revealed no relation between
carcinoids and small-cell lung carcinomas in gene pro-
duct immunophenotyping. The authors pointed out that
ACs and LCNECs should not be construed as inter-
mediate forms of these two tumor entities [37]. Folpe et
al. were able to detect TTF1 in 35% of all cases in TCs,
in 100% in ACs, in 75% in LCNECs and in 95% in
SCLCs. The authors also concluded that these results
suggest a common cell line origin of SCLCs and TCs
[38]. Du et al. described that TTF1 is expressed by neu-
roendocrine cell hyperplasia in 72.7%, by TCs in 27.8%,
by ACs in 29.4% and by LCNECs in 37.5% of all cases.
They also demonstrated that extrapulmonary neuroen-
docrine tumors are negative for TTF1, rating it to be
100% specific but not very sensitive for bronchopulmon-
ary carcinoids and possibly also LCNECs [39]. The pre-
dominance of TTF1 in carcinoids of bronchopulmonary
origin was confirmed by other studies [40-42]. In con-
trast to these and other publications, Cai et al. gave an
account of positive TTF1-expression in 69% of their stu-
died carcinoid cases, all tumors except one were TCs
[40]. In addition, immunohistochemical detection of
Mib1 and Bcl2 can be useful to differentiate between
recurrent and non-recurrent bronchopulmonary carci-
noid tumors [35]. The expression of CDX2 and PDX1 is
highly specific for identifying neuroendocrine tumors of
intestinal origin, since bronchopulmonary carcinoids
seem to be negative for these two markers. CK7 is pre-
dominantly found in adenocarcinomas of the lung. It is
also expressed by 63% of bronchopulmonary carcinoid
tumors and by 11% of gastrointestinal carcinoids. CK20
is mainly found in adenocarcinomas of the gastrointest-
inal tract, but not in bronchopulmonary carcinoid
tumors. Together with NESP-55, these mentioned mar-
kers can help to discriminate between neuroendocrine
tumors or adenocarcinomas of pulmonary and such of
extrapulmonary origin [34,40-43]. Chromoganin A
(CgA) and synaptophysin are commonly used neuroen-
docrine markers in immunohistochemical analysis [44].
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SCLCs has been reported previously [11,12]. In our case
report, the first diagnosis was metastasis of prostate can-
cer. After initial immunohistochemical stainings and due
to the therein reported expression of TTF1, CK7 and
the lack of CK20, this diagnosis was changed to primary
adenocarcinoma of the lung. Further immunohisto-
chemical stainings were performed. In consideration of
the slow tumor progression, the low Ki-67 labelling
index and the expression of CgA and synaptophysin, the
diagnosis was ultimately changed to TC. Up to this
time, we had already conducted a lobectomy to treat the
previously suspected adenocarcinoma. As Pelosi et al.
stated, careful evaluation of hematoxylin and eosin sec-
tions, together with the Ki-67 labelling index, remains
the most important tool in discriminating between car-
cinoids and SCLCs. An index below 20% is typical for
carcinoid tumors, whereas an index above 50% is usually
found in SCLCs.
GnrH receptors and the associated Raf-1/MEK/ERK-1/
2-pathway are potential targets for analogs in cancer
treatment. Activation of the Raf-1/MEK/ERK-1/2-path-
way by leflunomide and teriflunomide can inhibit prolif-
eration and growth of BON carcinoid cells in vitro and in
vivo and also decrease expression of neuroendocrine
markers in both BON and H727 carcinoid cells [45].
Similar effects have been reported for estradiol,
ZM336372 and tautomycin [46-50]. Kidd et al. detected
GnrH receptor expression in H720, but not in H727 cells
and GHRH receptor expression in H727, but not in H720
cells. According to their results for H720 cells, GnrH
+doxorubicin conjugate is a more effective proliferation
inhibitor in vitro than doxorubicin alone. In H727 cells,
this difference was not observed. Furthermore, GHRH
receptor antagonists have an antiproliferative effect in
H727 but not in H720 cells [51]. The signaling mechan-
isms of GnrH receptors differ significantly from cell type
to cell type. For example, signaling in COS7 cells is not
dependent on PKC. Since GnrH receptor expression has
not been studied in larger patient collectives with carci-
noid tumor disease, this raises the question whether
there is an association with the above mentioned Raf-1/
MEK/ERK-1/2-pathway and if its activation is dependent
on GnrH receptors [52]. If there is such a context, the
effects of agonists like leuprolide as a GnrH receptor ago-
nists may become of interest. Although we could not
detect GnrH-receptors in the examined specimen, there
may be individual differences in expression. In this
regard, GnrH receptor profiles in TCs and ACs should be
scrutinized. Further investigations could lead to new
therapeutical options in the treatment of TCs and espe-
cially ACs, since the GnrH receptor has been described
as located on the latter [51]. Clinically tested and
approved drugs such as leuprolide could come to use.
According to an analysis of eight studies by Gustafs-
son et al., approximately 58% of all patients show unspe-
cific symptoms: cough in 32%, hemoptysis in 26%,
pneumonia in 24% of all cases and, to a lesser extent,
fever, dyspnoe and chest pain. A carcinoid syndrome
occurs seldomly in approximately 1-3% [53]. Long term
obstruction typical for centrally localized tumors can
cause multiple bronchiectases in 19% of all patients [22].
Young and adult patients should undergo further exami-
nation if they show long-standing pulmonary symptoms
without any response to drug therapy [54,55]. To date
there is no laboratory test available that could always
detect a carcinoid reliably. Several serum markers are
used. CgA is a maker of carcinoids in general with a
high sensitivity (85.7%) and specificity (67.9%), although
it can also be detected in SCLCs depending on the clini-
cal stage [56,57]. The elevation of CgA can indicate the
recurrence of radically operated midgut carcinoid
tumors in 85% of all cases. The measurement of CgA
can be recommended for the continuous surveillance of
carcinoid patients [57,58]. However, CgA is also known
to be false positive in some cases, for example in
patients with multiple myeloma, renal impairment,
atrophic gastritis or proton pump inhibitor therapy [59].
The measurement of 5-HIAA and, according to the clin-
ical symptoms, of ACTH, MSH, GH etc. is only useful if
a carcinoid syndrome is suspected. Various diagnostic
methods are used in combination. Only 75% of all
patients show a suspicious chest X-ray. Despite a lack of
sensitivity and specificity, high resolution CT scans of
the abdomen and thorax are used most commonly for
an initial localization of the tumor. Carcinoid tumors
are known to be highly vascularized and may show a
strong contrast agent enhancement. MRI can provide
additional information.
68Ga-DOTA-peptide PET/CT
scans are currently the most accurate imaging proce-
dures for the diagnosis of NETs such as bronchial carci-
noids with a sensitivity of 97% and a specificity of 92%.
Even the detection of tumors smaller than 1 cm is pos-
sible. According to a study published by Ambrosini et
al.,
68Ga-DOTANOC PET/CT either affected stage or
caused a therapy modificati o ni nm o r et h a n5 0 %o ft h e
NET patients, proving its superiority to conventional
imaging [60]. In this context it should be noted that it
can be distinguished between endobronchial carcinoid
and inflammatory myofibroblastic tumors by combining
18F-FDG PET and
68Ga-DOTATOC PET/CT [61]. Prior
to this new method, somatostatin receptor scintigraphy
was used in imaging, which was not very specific for
bronchial carcinoids. A recently published study showed
that
68Ga-DOTANOC PET/CT is superior to
111In-pen-
tetreotide in the detection of CUP-NETs, with a locali-
zation rate of the primary tumor of 59% vs. 39%,
respectively. The authors concluded that this method
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with CUP-NETs [62]. Bronchial carcinoids are known to
be highly vascularized. Nevertheless they show a high
rate of false negative results in
18F-FDG PET, although
solitary cases of carcinoids with high
18F-FDG uptake
have been reported [63-65]. Interestingly, combined
diagnostic imaging with
131I-MIBG and
111In-pentetreo-
tide achieved an overall sensitivity of 95% for localiza-
tion of carcinoid tumors. However, this approach was
not further pursued [66]. According to the current
ACCP guidelines, transthoracic needle biopsy, broncho-
scopy or even surgical resection are appropriate means
of diagnosis for solitary pulmonary nodules of at least 8-
10 mm diameter. VATS, thoracotomy and mediastino-
scopy can be used in combination or as sole diagnostic
procedures [67]. Endo- and epibronchial ultrasound can
also provide further valuable information [68,69]. In this
regard, it is important to mention that transthoracic fine
needle aspiration biopsy bears the risk of nondiagnostic
biopsies. It is dependant on many different factors like
tumor size or needle diameter [67,70]. Also, there are
several reports on implantation metastasis caused by
fine needle aspiration biopsy. Although FNAB is consid-
ered to be a well-established diagnostic procedure, we
think the above mentioned limitations and complication
threaten the success of any curative therapy and should
not be ignored [71].
18F-FDG PET/CT scan is known to
be highly sensitive, yet has its limitations due to a lower
specifity. Like the above mentioned FNAB, a negative
PET/CT scan does not rule out the possiblity of malig-
nancy of a solitary pulmonary nodule and cannot
replace surgical resection [70]. Therefore, we did not see
the necessity to perform a preoperative PET/CT scan.
Since surgical resection is still considered to be the
most reliable diagnostic test [67,70], we prefer surgical
diagnostic procedures, if they are feasible. Histological
analysis with further immunohistochemical differentia-
tion still remains the gold standard in diagnosing
bronchopulmonary carcinoid tumors, with markers like
TTF1, CK7, CK20, chromogranin A, synaptophysin and
Ki-67 being used routinely.
Surgical resection is still considered to be gold stan-
dard in treatment. Nowadays, tissue-sparing procedures
become more and more popular, since they show no
great difference in long-term survival and a better post-
operative quality of life. For this purpose, early diagnosis
is essential. The extents of surgical resection and lymph
node dissection are still a matter of ongoing debate.
Some authors concluded that parenchyma sparing pro-
cedures in ACs should be avoided because of a higher
recurrence rate [25,72] and are suitable especially for
TCs. Others prefer more invasive procedures such as
lobectomy in combination with radical lymphadenect-
omy for any histological kind of carcinoid tumor
[20,22]. Endobronchial typical carcinoids with strictly
endoluminal growth and small tumor base are reported
to be treatable by bronchoscopic resection, showing
excellent long term results [69]. Wedge bronchoplasty
with large margins should be avoided due to the risk of
kinking of the tracheobronchial tree [73]. Some authors
pointed out that lymph node dissection should be per-
formed in any patients with atypical carcinoids [74,75],
whereas others recommended systematic lymphadenect-
omy in any carcinoid case [20,22,24,75]. Octreotide and
chemotherapy are normally used if a carcinoid syn-
drome or metastases are present. Kaplan et al. even
recommended postoperative radiochemotherapy for
patients with atypical carcinoids at stage I, reasoning it
with higher locoregional failure and distant metastasis
rates as compared to patients with typical carcinoids
[76]. According to the ACCP guidelines, there is level 2
C evidence for a conservative and observant approach in
case of a new diagnosed pulmonary tumor mass without
growth in the last 2 years. However, this strategy is not
used very often in practice, because tumors greater than
1.5 cm in diameter show high potential for malignancy
[67]. This approach should therefore be used with cau-
tion. Even after radical resection, distant metastases can
occur in 8% of all TC cases and are associated with a
worsening of prognosis.
The 10-year survival rate for typical carcinoids ranges
from 82% to 93%, for atypical carcinoids from 56% to
64% [8,69,72,75]. Modlin et al. described a 5-year survi-
val rate of 73,5% for all stages [6]. The various forms of
surgical resection techniques used nowadays normally
show excellent long-term results. Histology, evidence of
invasive growth, nodal status and the presence or
absence of distant metastases were identified as the
most important prognostic factors for long term survival
[6,7,26,72,75]. At the time of diagnosis, ACs usually
show a more advanced stage than TCs. According to a
recently published study, nodal invasion in TCs has no
influence on prognosis [9]. In contrast, Martini et al.
reported in 1994 that long term survival is independent
of lymph node metastases for both TCs and ACs and
that recurrence seems to depend more on cell type than
nodal status. However, this study only consisted of 25
patients [77]. In case of metastatic disease, TCs may
show a similar clinical course like ACs. If the metastases
are not resectable, the disease is considered to be incur-
able [53,78,79].
Conclusion
Misdiagnosis of bronchopulmonary carcinoid tumors
with surgical overtreatment can cause serious conse-
quences for the patient like intra- and postoperative
complications with further possible serious limitations of
lung function. The use of several immunohistochemical
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sections together with the Ki-67 labelling index are
important tools in discriminating between carcinoids and
other bronchopulmonary carcinomas. Simultaneously,
the pre-operative progression of the disease should be
considered before defining the extent of initial surgical
resection. In case of metastatic disease, TCs may show a
similar clinical course like ACs and a significant worsen-
ing of prognosis. Therefore, we think that even small
TCs which are considered as “stable disease” like our
reported case should be resected. Also, a 10-year follow
up is recommended.
GnrH receptors and the associated Raf-1/MEK/ERK-1/
2-pathway are potential targets for analogs in cancer
treatment. Activation of the above mentioned pathway
can inhibit proliferation and growth of various carcinoid
cell types. The typical carcinoid tumor described in our
case report showed almost no progression in 5 years.
The patient suffered from prostate cancer 4 years ago
and was treated with TUR-P, radiation therapy and the
application of leuprolide. We suspected a correlation
between the lack of tumor growth, application of leu-
prolide and the Raf-1/MEK/ERK-1/2-pathway. There-
fore, we examined GnrH receptor status in the
examined specimen. Although we could not detect
GnrH-receptors in the examined specimen, there may
be individual differences in expression. In this regard,
GnrH receptor profiles in TCs and ACs should be scru-
tinized. Further investigations could lead to new thera-
peutical options in the treatment of TCs and especially
ACs, since the GnrH receptor has already been
described on the latter. Clinically tested and approved
drugs such as leuprolide could come to use.
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